title: [Current management of myelodysplastic syndromes].
abstract: Treatment of myelodysplastic syndromes (MDS) has improved in recent years with better results of allogeneic stem cell therapy (SCT), the advent of new therapeutic options such as hypomethylating agents and lenalidomide, the introduction of iron chelation therapy and the implication of erythropoietic stimulating agents in the treatment of anemia. In this review, we summarize the different diagnostic and prognostic criteria and outline the different treatment options we have in 2011.
authors.affiliation: Service d'hématologie clinique, Département de médecine, CHU Sart-Tilman, Université de Liège, Belgique. jo.caers@chu.ulg.ac.be
authors.forename: J
authors.initials: J
authors.lastname: Caers
authors.forename: C
authors.initials: C
authors.lastname: Bonnet
authors.forename: C
authors.initials: C
authors.lastname: Graux
authors.forename: B
authors.initials: B
authors.lastname: De Prijck
authors.forename: Y
authors.initials: Y
authors.lastname: Beguin
mesh_terms: D000465:Algorithms; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000628:therapy*